lactic acid has been researched along with Cancer of Ovary in 56 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The transferring modified lipid coated PLGA nanoparticles, as a targetable vector, were developed for the targeting delivery of anticancer drugs with paclitaxel (PTX) as a model drug to the ovarian carcinoma, which combines the advantages and avoids disadvantages of polymeric nanoparticles and liposomes in drug delivery." | 7.80 | A targeting drug delivery system for ovarian carcinoma: transferrin modified lipid coated paclitaxel-loaded nanoparticles. ( Chen, XG; He, YX; Li, R; Wang, XY; Yang, WY; Yang, X; Zhang, Q, 2014) |
| "In vivo, treatment of an ovarian cancer mouse model with metformin resulted in greater tumor weight reduction in normoglycemic vs." | 5.42 | Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer. ( Eckert, MA; Johnson, A; Lengyel, E; Litchfield, LM; Mills, KA; Mukherjee, A; Pan, S; Romero, IL; Shridhar, V, 2015) |
| "The transferring modified lipid coated PLGA nanoparticles, as a targetable vector, were developed for the targeting delivery of anticancer drugs with paclitaxel (PTX) as a model drug to the ovarian carcinoma, which combines the advantages and avoids disadvantages of polymeric nanoparticles and liposomes in drug delivery." | 3.80 | A targeting drug delivery system for ovarian carcinoma: transferrin modified lipid coated paclitaxel-loaded nanoparticles. ( Chen, XG; He, YX; Li, R; Wang, XY; Yang, WY; Yang, X; Zhang, Q, 2014) |
| "Further, ovarian cancer cell line PEO1 was used to evaluate the toxicity and efficacy of nano-formulation by MTT assay." | 1.91 | Enhanced Anti-Proliferative Effect of Carboplatin in Ovarian Cancer Cells Exploiting Chitosan-Poly (Lactic Glycolic Acid) Nanoparticles. ( Alassaif, ER; Alassaif, FR; Dhanapal, J; Kaushik, AK, 2023) |
| "PITX2 has been earlier shown to induce ovarian cancer cell proliferation through the activation of different signaling cascades." | 1.91 | Oncogene-mediated nuclear accumulation of lactate promotes epigenetic alterations to induce cancer cell proliferation. ( Bandopadhyay, S; Chakrabarti, S; Ghosh, DD; Kamal, IM; Padmanaban, E; Roy, SS, 2023) |
| "Therefore, the glycolytic process of tumors could represent a therapeutic target, and agents that modify the energy metabolism of tumor cells have therapeutic potential." | 1.72 | Resveratrol reduces lactate production and modifies the ovarian cancer immune microenvironment. ( Chen, J; Chen, JG; He, JH; He, SY; Huang, ST; Huang, ZH; Lin, WM; Ye, HY, 2022) |
| "While the drug resistance of ovarian cancer cells has been extensively studied, the molecular mechanism of anticancer drug resistance under low-glucose conditions remains unknown." | 1.72 | Glucose deprivation enhances resistance to paclitaxel via ELAVL2/4-mediated modification of glycolysis in ovarian cancer cells. ( Choi, S; Jeong, JY; Kim, D; Park, GB; Yoon, YS, 2022) |
| "We investigated whether ovarian cancer metabolism could provide insight into the development of therapeutic strategies." | 1.46 | Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer. ( Chao, TK; Huang, RL; Huang, TS; Lai, HC; Liao, YP; Shen, HY; Su, PH; Wang, YC, 2017) |
| "Cell attachment of a human ovarian cancer cell line (OVCAR3) alone and co-cultured with mesenchymal stem cells (MSCs) was evaluated on flat and topographically nano-patterned surfaces." | 1.43 | The influence of nanotexturing of poly(lactic-co-glycolic acid) films upon human ovarian cancer cell attachment. ( Alexander, MR; Clarke, P; Collier, P; Marlow, M; Xue, X; Yaşayan, G, 2016) |
| "In addition, miR-203 promoted the metastasis of ovarian cancer cells in vivo and shorted the survival of the nude mice." | 1.43 | MiR-203 promotes the growth and migration of ovarian cancer cells by enhancing glycolytic pathway. ( Kejian, Z; Lichun, F; Na, X; Shaosheng, W; Xiaohong, Z; Xiaolan, X, 2016) |
| "Three ovarian cancer cell lines, HEY, SKOV3, and IGROV-1, were assayed for glutamine dependence by analyzing cytotoxicity, cell cycle progression, apoptosis, cell stress, and glucose/glutamine metabolism." | 1.42 | Glutamine promotes ovarian cancer cell proliferation through the mTOR/S6 pathway. ( Bae-Jump, VL; Guo, H; Jones, HM; Roque, DR; Sheng, X; Stine, JE; Willson, AK; Yuan, L; Zhou, C, 2015) |
| "In vivo, treatment of an ovarian cancer mouse model with metformin resulted in greater tumor weight reduction in normoglycemic vs." | 1.42 | Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer. ( Eckert, MA; Johnson, A; Lengyel, E; Litchfield, LM; Mills, KA; Mukherjee, A; Pan, S; Romero, IL; Shridhar, V, 2015) |
| "Epithelial ovarian cancer (EOC) is the most lethal and aggressive gynecological malignancy, and abnormal cellular metabolism significantly contributes to cancer onset and progression." | 1.42 | MicroRNA-29B (mir-29b) regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3. ( Chen, W; Fu, J; Li, X; Qu, K; Teng, Y; Yang, X; Zhang, Y, 2015) |
| "Cisplatin-resistant lung and ovarian cancer cell lines were used to evaluate the efficacy of metabolic inhibitors for selectively targeting cisplatin-resistant cells under varying oxygen conditions." | 1.40 | Targeting cisplatin-resistant human tumor cells with metabolic inhibitors. ( Brenneman, R; Kurtoglu, M; Lampidis, TJ; Liu, H; Sullivan, EJ, 2014) |
| "An altered metabolism during ovarian cancer progression allows for increased macromolecular synthesis and unrestrained growth." | 1.40 | Ovarian tumor-initiating cells display a flexible metabolism. ( Anderson, AS; Frisard, MI; Hulver, MW; Roberts, PC; Schmelz, EM, 2014) |
| "Paclitaxel was encapsulated in particles coated with a layer of polydopamine and a subsequent layer of poly(ethylene glycol) (PEG)." | 1.40 | Dual-layer surface coating of PLGA-based nanoparticles provides slow-release drug delivery to achieve metronomic therapy in a paclitaxel-resistant murine ovarian cancer model. ( Amoozgar, Z; Brandstoetter, T; Goldberg, MS; Wallis, SS; Wang, L; Wilson, EM, 2014) |
| "As in ovarian cancer cells, increased metabolic activity and glucose concentration has been linked to aggressiveness of cancer." | 1.39 | Therapeutic role of EF24 targeting glucose transporter 1-mediated metabolism and metastasis in ovarian cancer cells. ( Ben, W; Dong, L; Guan, Y; Huang, Y; Lu, M; Ning, N; Wang, Y; Yang, Y; Yuan, J; Zhang, D, 2013) |
| " Nanoparticles have shown promise in increasing the bioavailability of some chemicals." | 1.38 | Kaempferol nanoparticles achieve strong and selective inhibition of ovarian cancer cell viability. ( Chen, YC; Jiang, B; Jiang, BH; Li, B; Li, Z; Luo, H, 2012) |
| " In this study, we aimed to investigate the effect of PLGA nanoparticles encapsulating hPNAS-4 combined with cisplatin (DDP) on ovarian carcinoma." | 1.37 | Antitumor effects of PLGA nanoparticles encapsulating the human PNAS-4 gene combined with cisplatin in ovarian cancer. ( Bai, Y; Li, S; Liu, P; Qi, X; Song, X; Sun, C; Wei, Y; Xie, C; Yi, T; Zhao, X; Zheng, Y, 2011) |
| "This paper presents the pharmacokinetic of human growth hormone (hGH) implantable tablets tested on a human ovarian cancer mouse model." | 1.36 | Pharmacokinetics analysis of sustained release hGH biodegradable implantable tablets using a mouse model of human ovarian cancer. ( Dannies, P; Fariña, JB; Llabrés, M; Santoveña, A; Zhu, Y, 2010) |
| "The high recurrence and lethality of ovarian cancer at advanced stages is problematic, especially due to the development of numerous micrometastases scattered throughout the abdominal cavity." | 1.35 | Benefits of nanoencapsulation for the hypercin-mediated photodetection of ovarian micrometastases. ( Delie, F; Gurny, R; Lange, N; Zeisser-Labouèbe, M, 2009) |
| "A new dosage form of cisplatinum (CDDP), lactic acid oligomer microspheres incorporating cisplatinum (CDDP-ms), is designed to slowly release 70% of contained CDDP." | 1.28 | [Intracavitary microspheres incorporating cisplatinum in the treatment of malignant effusions--clinical trials]. ( Hagiwara, A; Ito, M; Iwamoto, A; Lee, M; Sasabe, T; Takahashi, T; Taniguchi, H; Wada, R; Yamaguchi, T; Yoneyama, C, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.57) | 18.7374 |
| 1990's | 3 (5.36) | 18.2507 |
| 2000's | 9 (16.07) | 29.6817 |
| 2010's | 34 (60.71) | 24.3611 |
| 2020's | 8 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Alassaif, FR | 1 |
| Alassaif, ER | 1 |
| Kaushik, AK | 1 |
| Dhanapal, J | 1 |
| Addley, S | 1 |
| McGowan, M | 1 |
| Asher, V | 1 |
| Bali, A | 1 |
| Abdul, S | 1 |
| Cullimore, V | 1 |
| Crossland, H | 1 |
| Phillips, A | 1 |
| Chen, J | 1 |
| Huang, ST | 1 |
| Chen, JG | 1 |
| He, JH | 1 |
| Lin, WM | 1 |
| Huang, ZH | 1 |
| Ye, HY | 1 |
| He, SY | 1 |
| Feng, Y | 1 |
| Zhang, X | 2 |
| Zhang, S | 1 |
| Xu, S | 1 |
| Chen, X | 3 |
| Zhou, C | 2 |
| Xi, Y | 1 |
| Xie, X | 1 |
| Lu, W | 1 |
| Bandopadhyay, S | 1 |
| Kamal, IM | 1 |
| Padmanaban, E | 1 |
| Ghosh, DD | 1 |
| Chakrabarti, S | 1 |
| Roy, SS | 1 |
| Song, R | 1 |
| Chai, T | 1 |
| Liu, J | 1 |
| Chu, A | 1 |
| Sun, C | 2 |
| Liu, Z | 1 |
| Kudo, K | 1 |
| Nomura, M | 1 |
| Sakamoto, Y | 1 |
| Ito, S | 1 |
| Morita, M | 1 |
| Kawai, M | 1 |
| Yamashita, Y | 1 |
| Ito, K | 1 |
| Yamada, H | 1 |
| Shima, H | 1 |
| Yaegashi, N | 1 |
| Tanuma, N | 1 |
| Park, GB | 1 |
| Jeong, JY | 1 |
| Choi, S | 1 |
| Yoon, YS | 1 |
| Kim, D | 1 |
| Chao, TK | 1 |
| Huang, TS | 1 |
| Liao, YP | 1 |
| Huang, RL | 1 |
| Su, PH | 1 |
| Shen, HY | 1 |
| Lai, HC | 1 |
| Wang, YC | 1 |
| Xia, H | 1 |
| Wang, W | 2 |
| Crespo, J | 1 |
| Kryczek, I | 1 |
| Li, W | 1 |
| Wei, S | 1 |
| Bian, Z | 1 |
| Maj, T | 1 |
| He, M | 1 |
| Liu, RJ | 1 |
| He, Y | 1 |
| Rattan, R | 1 |
| Munkarah, A | 1 |
| Guan, JL | 1 |
| Zou, W | 1 |
| Nonomiya, Y | 1 |
| Noguchi, K | 1 |
| Katayama, K | 1 |
| Sugimoto, Y | 1 |
| Liu, D | 1 |
| Li, H | 1 |
| Zou, L | 2 |
| Song, X | 3 |
| Yi, T | 3 |
| Li, S | 3 |
| Deng, H | 1 |
| Li, Z | 2 |
| Bai, Y | 2 |
| Zhong, Q | 1 |
| Wei, Y | 3 |
| Zhao, X | 3 |
| Anderson, AS | 2 |
| Roberts, PC | 2 |
| Frisard, MI | 2 |
| McMillan, RP | 1 |
| Brown, TJ | 1 |
| Lawless, MH | 1 |
| Hulver, MW | 2 |
| Schmelz, EM | 2 |
| Gullotti, E | 1 |
| Park, J | 1 |
| Yeo, Y | 1 |
| Zhang, D | 1 |
| Wang, Y | 4 |
| Dong, L | 1 |
| Huang, Y | 2 |
| Yuan, J | 1 |
| Ben, W | 1 |
| Yang, Y | 1 |
| Ning, N | 1 |
| Lu, M | 1 |
| Guan, Y | 1 |
| Liu, P | 2 |
| Duan, Y | 1 |
| Yin, X | 1 |
| Wang, Q | 2 |
| Liu, X | 1 |
| Wang, X | 3 |
| Zhou, J | 1 |
| Qiu, L | 1 |
| Di, W | 1 |
| Sullivan, EJ | 1 |
| Kurtoglu, M | 1 |
| Brenneman, R | 1 |
| Liu, H | 1 |
| Lampidis, TJ | 1 |
| Li, R | 1 |
| Zhang, Q | 1 |
| Wang, XY | 1 |
| Chen, XG | 1 |
| He, YX | 1 |
| Yang, WY | 1 |
| Yang, X | 2 |
| Li, G | 1 |
| Mao, F | 1 |
| Li, X | 3 |
| Liu, Q | 1 |
| Chen, L | 1 |
| Lv, L | 1 |
| Wu, J | 1 |
| Dai, W | 1 |
| Wang, G | 1 |
| Zhao, E | 1 |
| Tang, KF | 1 |
| Sun, ZS | 1 |
| Bai, MY | 1 |
| Liu, SZ | 1 |
| Babu, A | 1 |
| Muralidharan, R | 1 |
| Shanker, M | 1 |
| Munshi, A | 1 |
| Ramesh, R | 1 |
| Amoozgar, Z | 1 |
| Wang, L | 1 |
| Brandstoetter, T | 1 |
| Wallis, SS | 1 |
| Wilson, EM | 1 |
| Goldberg, MS | 1 |
| Malm, SW | 1 |
| Hanke, NT | 1 |
| Gill, A | 1 |
| Carbajal, L | 1 |
| Baker, AF | 1 |
| Yuan, L | 1 |
| Sheng, X | 1 |
| Willson, AK | 1 |
| Roque, DR | 1 |
| Stine, JE | 1 |
| Guo, H | 1 |
| Jones, HM | 1 |
| Bae-Jump, VL | 1 |
| Peng, C | 1 |
| Su, J | 1 |
| Zeng, W | 1 |
| Litchfield, LM | 1 |
| Mukherjee, A | 1 |
| Eckert, MA | 1 |
| Johnson, A | 1 |
| Mills, KA | 1 |
| Pan, S | 1 |
| Shridhar, V | 1 |
| Lengyel, E | 1 |
| Romero, IL | 1 |
| Xintaropoulou, C | 1 |
| Ward, C | 1 |
| Wise, A | 1 |
| Marston, H | 1 |
| Turnbull, A | 1 |
| Langdon, SP | 1 |
| Teng, Y | 1 |
| Zhang, Y | 2 |
| Qu, K | 1 |
| Fu, J | 1 |
| Chen, W | 1 |
| Yaşayan, G | 1 |
| Xue, X | 1 |
| Collier, P | 1 |
| Clarke, P | 1 |
| Alexander, MR | 1 |
| Marlow, M | 1 |
| Battista, MJ | 1 |
| Goetze, K | 1 |
| Schmidt, M | 1 |
| Cotarelo, C | 1 |
| Weyer-Elberich, V | 1 |
| Hasenburg, A | 1 |
| Mueller-Klieser, W | 1 |
| Walenta, S | 1 |
| Li, B | 2 |
| Ni, Z | 1 |
| Zeng, Y | 1 |
| Yan, X | 1 |
| He, J | 1 |
| Lyu, X | 1 |
| Wu, Y | 1 |
| Zheng, Y | 2 |
| He, F | 1 |
| Lü, JM | 1 |
| Liang, Z | 1 |
| Gu, J | 1 |
| Yao, Q | 1 |
| Chen, C | 1 |
| Xiaohong, Z | 1 |
| Lichun, F | 1 |
| Na, X | 1 |
| Kejian, Z | 1 |
| Xiaolan, X | 1 |
| Shaosheng, W | 1 |
| Alberti, D | 1 |
| Protti, N | 1 |
| Franck, M | 1 |
| Stefania, R | 1 |
| Bortolussi, S | 1 |
| Altieri, S | 1 |
| Deagostino, A | 1 |
| Aime, S | 1 |
| Geninatti Crich, S | 1 |
| Bernacchioni, C | 1 |
| Ghini, V | 1 |
| Cencetti, F | 1 |
| Japtok, L | 1 |
| Donati, C | 1 |
| Bruni, P | 1 |
| Turano, P | 1 |
| Zeisser-Labouèbe, M | 2 |
| Delie, F | 3 |
| Gurny, R | 3 |
| Lange, N | 2 |
| Yang, Q | 1 |
| Kang, YQ | 1 |
| Wang, HJ | 1 |
| Yin, GF | 1 |
| Fang, K | 1 |
| Yang, K | 1 |
| Hernlund, E | 1 |
| Hjerpe, E | 1 |
| Avall-Lundqvist, E | 1 |
| Shoshan, M | 1 |
| Santoveña, A | 1 |
| Fariña, JB | 1 |
| Llabrés, M | 1 |
| Zhu, Y | 1 |
| Dannies, P | 1 |
| Hanlon, DJ | 1 |
| Aldo, PB | 1 |
| Devine, L | 1 |
| Alvero, AB | 1 |
| Engberg, AK | 1 |
| Edelson, R | 1 |
| Mor, G | 1 |
| Qi, X | 1 |
| Xie, C | 1 |
| Luo, H | 1 |
| Jiang, B | 1 |
| Jiang, BH | 1 |
| Chen, YC | 1 |
| DE ROETTH, H | 1 |
| RAMKISSOON, RA | 1 |
| CHAMBERLAIN, NO | 1 |
| BAKER, EL | 1 |
| JENNINGS, ER | 1 |
| Kang, BK | 1 |
| Chon, SK | 1 |
| Kim, SH | 1 |
| Jeong, SY | 1 |
| Kim, MS | 1 |
| Cho, SH | 1 |
| Lee, HB | 1 |
| Khang, G | 1 |
| Hascalik, S | 1 |
| Celik, O | 1 |
| Erdem, G | 1 |
| Cirstoiu-Hapca, A | 1 |
| Bossy-Nobs, L | 1 |
| Buchegger, F | 1 |
| Kumagai, S | 1 |
| Sugiyama, T | 1 |
| Nishida, T | 1 |
| Ushijima, K | 1 |
| Yakushiji, M | 1 |
| Boss, EA | 1 |
| Moolenaar, SH | 1 |
| Massuger, LF | 1 |
| Boonstra, H | 1 |
| Engelke, UF | 1 |
| de Jong, JG | 1 |
| Wevers, RA | 1 |
| Okada, T | 1 |
| Harada, M | 1 |
| Matsuzaki, K | 1 |
| Nishitani, H | 1 |
| Aono, T | 1 |
| Hagiwara, A | 1 |
| Takahashi, T | 1 |
| Yamaguchi, T | 1 |
| Taniguchi, H | 1 |
| Iwamoto, A | 1 |
| Yoneyama, C | 1 |
| Ito, M | 1 |
| Sasabe, T | 1 |
| Lee, M | 1 |
| Wada, R | 1 |
| Broxterman, HJ | 1 |
| Pinedo, HM | 1 |
| Schuurhuis, GJ | 1 |
| Lankelma, J | 1 |
56 other studies available for lactic acid and Cancer of Ovary
| Article | Year |
|---|---|
Enhanced Anti-Proliferative Effect of Carboplatin in Ovarian Cancer Cells Exploiting Chitosan-Poly (Lactic Glycolic Acid) Nanoparticles.
Topics: Carboplatin; Chitosan; Drug Carriers; Female; Glycols; Humans; Lactic Acid; Nanoparticles; Ovarian N | 2023 |
Lactate Is a Reliable Predictor of ICU Length of Stay Following Ultra-radical Ovarian Cancer Surgery.
Topics: Female; Humans; Intensive Care Units; Lactic Acid; Length of Stay; Ovarian Neoplasms; Retrospective | 2022 |
Resveratrol reduces lactate production and modifies the ovarian cancer immune microenvironment.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Immune Checkpoint Inhibitors; Lactic Acid; Neoplasms; | 2022 |
PGAM1 Promotes Glycolytic Metabolism and Paclitaxel Resistance via Pyruvic Acid Production in Ovarian Cancer Cells.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Glycolysis; Humans; Lactic Acid; Ovarian Neopla | 2022 |
Oncogene-mediated nuclear accumulation of lactate promotes epigenetic alterations to induce cancer cell proliferation.
Topics: Animals; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Epigenesis, Genetic; Female; Gene Exp | 2023 |
Knockdown of circMFN2 inhibits cell progression and glycolysis by miR-198/CUL4B pathway in ovarian cancer.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cullin Proteins; Disease Models, Animal; Female; Glyc | 2023 |
Divergent metabolic responses dictate vulnerability to NAMPT inhibition in ovarian cancer.
Topics: Acrylamides; Cell Line, Tumor; Cytokines; Female; Glycolysis; Humans; Lactic Acid; NAD; Niacin; Nico | 2020 |
Glucose deprivation enhances resistance to paclitaxel via ELAVL2/4-mediated modification of glycolysis in ovarian cancer cells.
Topics: Antineoplastic Agents; Caspases; Cell Line, Tumor; Drug Resistance, Neoplasm; ELAV-Like Protein 2; E | 2022 |
Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer.
Topics: Animals; Biomarkers; Cell Line, Tumor; Cell Survival; Disease-Free Survival; Enzyme Inhibitors; Fema | 2017 |
Suppression of FIP200 and autophagy by tumor-derived lactate promotes naïve T cell apoptosis and affects tumor immunity.
Topics: Animals; Apoptosis; Autophagy; Autophagy-Related Proteins; Cell Line, Tumor; Female; Gene Expression | 2017 |
Novel pharmacological effects of poly (ADP-ribose) polymerase inhibitor rucaparib on the lactate dehydrogenase pathway.
Topics: Cell Line, Tumor; Female; Humans; Indoles; L-Lactate Dehydrogenase; Lactic Acid; Ovarian Neoplasms; | 2019 |
Long non-coding RNA GEHT1 promoted the proliferation of ovarian cancer cells via modulating the protein stability of HIF1α.
Topics: Apoptosis; Biological Transport; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regul | 2019 |
Administration of PLGA nanoparticles carrying shRNA against focal adhesion kinase and CD44 results in enhanced antitumor effects against ovarian cancer.
Topics: Animals; Apoptosis; Cell Proliferation; Female; Focal Adhesion Protein-Tyrosine Kinases; Gene Knockd | 2013 |
Metabolic changes during ovarian cancer progression as targets for sphingosine treatment.
Topics: Animals; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Respiration; Cholesterol; Citrate (si | 2013 |
Polydopamine-based surface modification for the development of peritumorally activatable nanoparticles.
Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Carriers; Female; Gen | 2013 |
Therapeutic role of EF24 targeting glucose transporter 1-mediated metabolism and metastasis in ovarian cancer cells.
Topics: Animals; Benzylidene Compounds; Biological Transport; Cell Line, Tumor; Cell Movement; Cell Prolifer | 2013 |
Specific cell targeting with APRPG conjugated PEG-PLGA nanoparticles for treating ovarian cancer.
Topics: Angiogenesis Inhibitors; Animals; Cyclohexanes; Drug Delivery Systems; Female; Human Umbilical Vein | 2014 |
Targeting cisplatin-resistant human tumor cells with metabolic inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Deoxyglucose; Drug Resistance, Neoplasm; Female; | 2014 |
A targeting drug delivery system for ovarian carcinoma: transferrin modified lipid coated paclitaxel-loaded nanoparticles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma; Cell Line, Tumor; Chemistry, Pharmaceutical; | 2014 |
Ras-induced epigenetic inactivation of the RRAD (Ras-related associated with diabetes) gene promotes glucose uptake in a human ovarian cancer model.
Topics: Adult; Aged; Animals; Biological Transport; Carcinogenesis; Cell Line, Tumor; Cell Transformation, N | 2014 |
A simple and general method for preparing antibody-PEG-PLGA sub-micron particles using electrospray technique: an in vitro study of targeted delivery of cisplatin to ovarian cancer cells.
Topics: Antibodies; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Delivery Systems; Female; Fluoresc | 2014 |
Efficient inhibition of intraperitoneal human ovarian cancer growth by short hairpin RNA targeting CD44.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Female; Humans; Hyaluronan Receptors; Lact | 2014 |
Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/Plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Chitosan; Cisplatin; Drug Delivery Systems; | 2014 |
Ovarian tumor-initiating cells display a flexible metabolism.
Topics: Animals; Apoptosis; Blotting, Western; Cell Proliferation; Cell Transformation, Neoplastic; Disease | 2014 |
Dual-layer surface coating of PLGA-based nanoparticles provides slow-release drug delivery to achieve metronomic therapy in a paclitaxel-resistant murine ovarian cancer model.
Topics: Administration, Metronomic; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Delayed-Ac | 2014 |
The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines.
Topics: Antineoplastic Agents; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Deoxyglucose; Dose-Respon | 2015 |
Glutamine promotes ovarian cancer cell proliferation through the mTOR/S6 pathway.
Topics: Adenosine Triphosphate; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Transforma | 2015 |
TNFR1 Regulates Ovarian Cancer Cell Tumorigenicity Through PIK3CB-p110Beta.
Topics: Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Class I Phosphatidylinositol 3-Kinases; | 2015 |
Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer.
Topics: Animals; Antineoplastic Agents; Ascites; Cell Line, Tumor; Cell Survival; Female; Gene Expression Re | 2015 |
A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Hypoxia; Cell Proliferation; Dose-Response | 2015 |
MicroRNA-29B (mir-29b) regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3.
Topics: 3' Untranslated Regions; Animals; Apoptosis; Blotting, Western; Carcinoma, Ovarian Epithelial; Cell | 2015 |
The influence of nanotexturing of poly(lactic-co-glycolic acid) films upon human ovarian cancer cell attachment.
Topics: Cell Line, Tumor; Female; Humans; Lactic Acid; Ovarian Neoplasms; Polyglycolic Acid; Polylactic Acid | 2016 |
Feasibility of induced metabolic bioluminescence imaging in advanced ovarian cancer patients: first results of a pilot study.
Topics: Aged; Aged, 80 and over; Carcinoma, Ovarian Epithelial; Disease Progression; Energy Metabolism; Feas | 2016 |
Dichloroacetate and metformin synergistically suppress the growth of ovarian cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Dichloroacetic Acid; Drug Sy | 2016 |
New polymer of lactic-co-glycolic acid-modified polyethylenimine for nucleic acid delivery.
Topics: Animals; Cell Line, Tumor; Cell Survival; DNA; Female; Genetic Therapy; HEK293 Cells; Humans; Lactic | 2016 |
MiR-203 promotes the growth and migration of ovarian cancer cells by enhancing glycolytic pathway.
Topics: 3' Untranslated Regions; Animals; Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferatio | 2016 |
Theranostic Nanoparticles Loaded with Imaging Probes and Rubrocurcumin for Combined Cancer Therapy by Folate Receptor Targeting.
Topics: 3T3 Cells; Animals; Cell Line, Tumor; Cell Proliferation; Coordination Complexes; Curcumin; Drug Car | 2017 |
NMR metabolomics highlights sphingosine kinase-1 as a new molecular switch in the orchestration of aberrant metabolic phenotype in cancer cells.
Topics: Adenocarcinoma; Animals; Carbon Dioxide; Cell Cycle Proteins; Cell Line, Tumor; Female; Glucose; Glu | 2017 |
Benefits of nanoencapsulation for the hypercin-mediated photodetection of ovarian micrometastases.
Topics: Animals; Anthracenes; Disease Models, Animal; Drug Delivery Systems; Endoscopy; Female; Fluorescence | 2009 |
[Controlled release of paclitaxel from microparticles containing PLLA and its anti-tumor activity on human ovarian carcinoma cell line].
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Delayed-Action P | 2009 |
Ovarian carcinoma cells with low levels of beta-F1-ATPase are sensitive to combined platinum and 2-deoxy-D-glucose treatment.
Topics: Antimetabolites; Antineoplastic Agents; Apoptosis; Blotting, Western; Carboplatin; Cell Proliferatio | 2009 |
Pharmacokinetics analysis of sustained release hGH biodegradable implantable tablets using a mouse model of human ovarian cancer.
Topics: Animals; Cell Proliferation; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; Dru | 2010 |
Enhanced stimulation of anti-ovarian cancer CD8(+) T cells by dendritic cells loaded with nanoparticle encapsulated tumor antigen.
Topics: Antigen Presentation; Antigens, Differentiation; Antigens, Neoplasm; Carcinoma; CD8-Positive T-Lymph | 2011 |
Antitumor effects of PLGA nanoparticles encapsulating the human PNAS-4 gene combined with cisplatin in ovarian cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Body Weight; Carbon-Nitrog | 2011 |
Kaempferol nanoparticles achieve strong and selective inhibition of ovarian cancer cell viability.
Topics: Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Female | 2012 |
Chemical characteristics and varying degrees of malignancy in tumors of the human ovary. I. Oxygen consumption and lactic acid production.
Topics: Female; Humans; Lactic Acid; Metabolism; Neoplasms; Ovarian Neoplasms; Ovary; Oxygen Consumption | 1957 |
DIAGNOSTIC SIGNIFICANCE OF URINARY LACTIC ACID DEHYDROGENASE.
Topics: Adenocarcinoma; Albuminuria; Carcinoma, Papillary; Carcinoma, Transitional Cell; Clinical Enzyme Tes | 1964 |
Controlled release of paclitaxel from microemulsion containing PLGA and evaluation of anti-tumor activity in vitro and in vivo.
Topics: Animals; Cell Death; Cell Line, Tumor; Drug Delivery Systems; Drug Screening Assays, Antitumor; Drug | 2004 |
Magnetic resonance spectral analysis of ovarian teratomas.
Topics: Choline; Creatine; Female; Humans; Lactic Acid; Lipids; Magnetic Resonance Spectroscopy; Ovarian Neo | 2005 |
Hypericin-loaded nanoparticles for the photodynamic treatment of ovarian cancer.
Topics: Animals; Anthracenes; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Delivery Systems; Female; Hu | 2006 |
Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; A | 2007 |
Improvement of intraperitoneal chemotherapy for rat ovarian cancer using cisplatin-containing microspheres.
Topics: Animals; Antineoplastic Agents; Chemistry, Pharmaceutical; Cisplatin; Female; Injections, Intraperit | 1996 |
High-resolution proton nuclear magnetic resonance spectroscopy of ovarian cyst fluid.
Topics: Adult; Amino Acids; Aspartic Acid; Blood Glucose; Body Fluids; Cyst Fluid; Cystadenoma, Serous; Fema | 2000 |
Evaluation of female intrapelvic tumors by clinical proton MR spectroscopy.
Topics: Adult; Aged; Aged, 80 and over; Choline; Creatine; Diagnosis, Differential; Energy Metabolism; Femal | 2001 |
[Intracavitary microspheres incorporating cisplatinum in the treatment of malignant effusions--clinical trials].
Topics: Animals; Ascitic Fluid; Cisplatin; Delayed-Action Preparations; Female; Humans; Infusions, Intraveno | 1990 |
Cyclosporin A and verapamil have different effects on energy metabolism in multidrug-resistant tumour cells.
Topics: Adenosine Monophosphate; Adenosine Triphosphate; Cell Line; Cyclosporins; Daunorubicin; Drug Resista | 1990 |